Nuvation Bio receives a Moderate Buy rating based on its undervalued oncology assets, primarily the commercial-stage drug Ibtrozi (taletrectinib) and the late-stage safusidenib. The analyst values the company at $5.60 per share, citing potential upside from mergers and acquisitions and milestone payments. Risks include revenue growth uncertainty for Ibtrozi and clinical risks for safusidenib, but a strong balance sheet reduces dilution concerns. This marks Nuvation's transition to a commercial-stage oncology firm following FDA approval of Ibtrozi in June 2025.
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
BMW is recalling 29,119 plug-in hybrid sedans due to a potential fire risk caused by corrosion in the engine starter's electrical relay. This defect can lead to a short circuit and overheating even when the vehicle is parked with the ignition off. Th...
